Information

Dear user, the application need JavaScript support. Please enable JavaScript in your browser.

You are browsing as a GUEST
Title of the item:

Cisplatin/fluorouracil: Grade 1 blood reaction: case report.

Title :
Cisplatin/fluorouracil: Grade 1 blood reaction: case report.
Subject Terms :
FLUOROURACIL
CISPLATIN
NEOADJUVANT chemotherapy
NASOPHARYNX cancer
Source :
Reactions Weekly; 4/24/2021, Vol. 1852 Issue 1, p133-133, 1p
Periodical
Subsequently, the patient developed grade 1 blood reaction related to the treatment, which was continued till the cut-off date. The patient, who had LANPC, started receiving cisplatin 80 mg/m SP 2 sp on day 1 plus fluorouracil [5-fluorouracil] 800 mg/m SP 2 sp on days 1-5, once every 28 days cycle. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event In a retrospective study involving 60 locally advanced nasopharyngeal carcinoma (LANPC) patients admitted to a hospital between August 2010 and June 2016 (China), a patient [ I age and sex not stated i ] was described, who developed grade 1 blood reaction during treatment with cisplatin and fluorouracil [ I routes and duration of treatments to reaction onset not stated i ]. [Extracted from the article]
Copyright of Reactions Weekly is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

We use cookies to help identify your computer so we can tailor your user experience, track shopping basket contents and remember where you are in the order process.